GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2014
Non-Hodgkin's lymphomas, version 4.2014.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04587388 (Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients), which is not on this map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Pooled it
- Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients.Annals of hematology · 2020Pooled it
- Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.Cancer chemotherapy and pharmacology · 2023Trial
- Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.Annals of hematology · 2022Trial
- Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.Journal of global oncology · 2019Trial
- Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.British journal of haematology · 2019Trial
- Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.BioMed research international · 2016Trial
- CD5-positive diffuse large B-cell lymphoma of the uterus: a Case Report with cytologic findings from uterine cavity drainage and literature review.Frontiers in oncology · 2026Article
- Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.HemaSphere · 2025Article
- Cardiovascular disease in adolescent and young adult survivors of non-Hodgkin lymphoma in Korea.Journal of cancer survivorship : research and practice · 2025Article
- Upregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma.Discover oncology · 2025Article
- Zanubrutinib: past, present, and future.Blood cancer journal · 2023Review
- A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.Journal of ovarian research · 2023Article
- Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.CPT: pharmacometrics & systems pharmacology · 2023Article
- Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.PharmacoEconomics - open · 2022Article
- Routine Pathologic Examination of Femoral Head Specimens from Total Hip Arthroplasty May Not Be Indicated or Cost-effective: A Systematic Review.Arthroplasty today · 2022Article
- Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.Clinical lymphoma, myeloma & leukemia · 2022Article
- Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.Clinical lymphoma, myeloma & leukemia · 2022Article
- Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.Oncotarget · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.